Mann Paul Elliot
Known title: Chief Executive OfficerCIK: 0001744816
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
Abeona Reports ZEVASKYN Launch Momentum and Revenue Growth. Abeona Therapeutics highlighted positive momentum for its ZEVASKYN product launch and revenue growth during a recent H.C. Wainwright event. The company is also expanding its distribution network as the treatment for RDEB gains traction. These developments provide fundamental context for the stock, which is currently trading near its 52-week low.
Transaction History
| ASPI | ▼ Sell | Open Market | 83,759 | $343K | 9/4/2026 | View on chart |
| ASPI | ▼ Sell | Open Market | 83,758 | $328K | 9/3/2026 | View on chart |
| ASPI | ▼ Sell | Open Market | 83,758 | $327K | 9/2/2026 | View on chart |
| ASPI | ▼ Sell | Open Market | 83,759 | $650K | 6/3/2026 | View on chart |
| ASPI | ▼ Sell | Open Market | 83,758 | $694K | 6/2/2026 | View on chart |
| ASPI | ▼ Sell | Open Market | 83,758 | $660K | 6/1/2026 | View on chart |
| ASPI | ▲ Buy | Grant | 2,233,555 | — | 5/28/2026 | View on chart |
| ASPI | ▼ Sell | Open Market | 162,153 | $881K | 3/2/2026 | View on chart |
| ASPI | ▼ Sell | Open Market | 162,153 | $933K | 12/1/2025 | View on chart |
| ASPI | ▼ Sell | Open Market | 50,000 | $288K | 11/25/2025 | View on chart |
| ASPI | ▼ Sell | Open Market | 112,500 | $845K | 11/17/2025 | View on chart |
| ASPI | ▲ Buy | Option Exercise | 216,000 | $432K | 9/9/2025 | View on chart |
| ASPI | ▼ Sell | Tax Withholding | 50,644 | $432K | 9/9/2025 | View on chart |
| ASPI | ▲ Buy | Option Exercise | 1,000,000 | $2.0M | 9/9/2025 | View on chart |
| ASPI | ▼ Sell | Tax Withholding | 234,466 | $2.0M | 9/9/2025 | View on chart |
| ASPI | ▼ Sell | Open Market | 81,077 | $680K | 9/9/2025 | View on chart |
| ASPI | ▼ Sell | Open Market | 81,076 | $691K | 9/8/2025 | View on chart |
| ASPI | ▼ Sell | Open Market | 316,666 | $1.8M | 4/17/2025 | View on chart |
| ASPI | ▼ Sell | Open Market | 316,667 | $1.7M | 4/16/2025 | View on chart |
| ASPI | ▼ Sell | Open Market | 316,667 | $1.8M | 4/15/2025 | View on chart |
| ASPI | ▲ Buy | Grant | 1,441,361 | — | 4/14/2025 | View on chart |
| ASPI | ▲ Buy | Grant | 978,466 | — | 9/6/2024 | View on chart |
| ASPI | ▲ Buy | Open Market | 39,984 | — | 7/15/2024 | View on chart |
| ASPI | ▲ Buy | Grant | 718,143 | $0 | 3/1/2023 | View on chart |
| ASPI | ▲ Buy | Grant | 1,000,000 | $0 | 12/30/2022 | View on chart |
| ASPI | ▲ Buy | Grant | 1,000,000 | $0 | 11/15/2022 | View on chart |
| ASPI | ▲ Buy | Grant | 37,500 | $150K | 11/15/2022 | View on chart |
| ABEO | ▲ Buy | Grant | 13,400 | $0 | 9/26/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
CarMax Earnings Drive Market Rally, Affecting ASPI
CarMax reported stronger Q2 earnings, sparking a rally in several large stocks. The article notes that this market move lifted many shares, including ASPI, which is currently trading near its 52‑week low. While ASPI is not directly involved, the broader positive sentiment could support its price. The rally may provide a short‑term lift for ASPI as investors seek opportunities in the market.
CarMax Earnings Drive Market Rally, Affecting ASPI. CarMax reported stronger Q2 earnings, sparking a rally in several large stocks. The article notes that this market move lifted many shares, including ASPI, which is currently trading near its 52‑week low. While ASPI is not directly involved, the broader positive sentiment could support its price. The rally may provide a short‑term lift for ASPI as investors seek opportunities in the market.